3041-22: Ketamine Treatment Strategies – 4 years of Experience in a Clinical Setting

The development of a ketamine service, including IV ketamine infusion and intranasal esketamine administration, with a clinical team approach to patient management has proved safe, effective and offers adjunct therapy for those with treatment-resistant depression and suicidality.  Lessons learned and current research will be reviewed.

Presenters: Paula Bolton, MS, CNP, ANP-BC; Courtney Miller, RN, ADN, BA

Disclosures:  The APNA planners and faculty have no relevant financial relationships to disclose. Off-label uses will be discussed during this presentation.

Session Length:  46 minutes

Target Audience:  RN, APRN

Learning Outcome:
Upon completion of this presentation, the participant will be able to:

• Describe the effectiveness and safety concerns in the operation of a ketamine service, incorporating IV ketamine infusion and esketamine intranasal options.

Keywords: Ketamine, Esketamine, Treatment Resistant Depression

Nursing Continuing Professional Development:
0.75 pharmacology contact hours.  * In order to receive contact hours, you must: Listen to presentation, complete an evaluation, and earn a passing score on the post-test before the expiration date. You will have 5 tries to correctly answer the questions on the post-test and a score of 80% is required to pass. Once you have passed and completed an evaluation, the certificate will be generated online, available for you to print immediately. You cannot earn credit unless all steps are completed.

The American Psychiatric Nurses Association is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Originally Presented
APNA 36th Annual Conference
Long Beach, CA

The contact hours for this session expire:  November 30, 2025